Investor Alert: Pomerantz Law Firm Investigates Entrada Therapeutics for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud involving Entrada Therapeutics (TRDA) following a significant drop in its stock price after the release of underwhelming clinical trial results. The firm claims that the reported 2.36% increase in dystrophin production was insufficient to make their drug competitive, leading investors to contact Pomerantz for legal action.
Tickers: $TRDA
Topics: clinical_trial_results investor_protection stock_price_drop